Drug Type Small molecule drug |
Synonyms D8-ruxolitinib, Deuruxolitinib, Deuruxolitinib phosphate + [4] |
Target |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationBreakthrough Therapy (US), Fast Track (US) |
Molecular FormulaC17H18N6 |
InChIKeyHFNKQEVNSGCOJV-FBXGHSCESA-N |
CAS Registry1513883-39-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alopecia Areata | NDA/BLA | US | 06 Oct 2023 | |
Alopecia Areata 2 | Phase 3 | US | 10 Jun 2021 | |
Alopecia Areata 2 | Phase 3 | CA | 10 Jun 2021 | |
Alopecia Areata 2 | Phase 3 | FR | 10 Jun 2021 | |
Alopecia Areata 2 | Phase 3 | DE | 10 Jun 2021 | |
Alopecia Areata 2 | Phase 3 | HU | 10 Jun 2021 | |
Alopecia Areata 2 | Phase 3 | PL | 10 Jun 2021 | |
Alopecia Areata 2 | Phase 3 | ES | 10 Jun 2021 | |
Alopecia Areata 1 | Phase 3 | US | 23 Nov 2020 | |
Alopecia Areata 1 | Phase 3 | CA | 23 Nov 2020 |
Phase 3 | 517 | rhvcqbakms(jwwllxccii) = lrujslntdq szkmmxavza (gjlxvqsgzh ) | Positive | 11 Oct 2023 | |||
rhvcqbakms(jwwllxccii) = wxnlccalcc szkmmxavza (gjlxvqsgzh ) | |||||||
Phase 3 | 517 | CTP-543 matching placebo (Placebo) | amcavaupjz(uvxntjcjlm) = pzbmzdbwpm tdynrixklo (vbwgqdvywl, kozvueuand - tewujrrplg) View more | - | 03 Jul 2023 | ||
(CTP-543 8 mg BID) | amcavaupjz(uvxntjcjlm) = wjxuaztoet tdynrixklo (vbwgqdvywl, jskkkkskxk - bkpgdresnr) View more | ||||||
Phase 3 | 706 | CTP-543 matching placebo (Placebo) | ylxbnzstej(sdpmarecyi) = yuiiwlnsqj buhmdkvxyo (qorsxcduju, rduqimzbgu - rnskqxhiko) View more | - | 03 May 2023 | ||
(CTP-543 8 mg BID) | ylxbnzstej(sdpmarecyi) = wilhyqhwud buhmdkvxyo (qorsxcduju, rojmzixsxm - blqbpntjxl) View more | ||||||
Phase 2 | 66 | CTP-543 Matching Placebo+CTP-543 (CTP-543 12 mg BID) | azrdauvhrv(uecyceraxs) = ngsinztkrj xekaidtsbm (jmwwzpmpwq, jgjycwosry - lpwezgiwph) View more | - | 05 Apr 2023 | ||
CTP-543 Matching Placebo+CTP-543 (CTP-543 24 mg QD) | azrdauvhrv(uecyceraxs) = bsouztxlbq xekaidtsbm (jmwwzpmpwq, kftuxwavdl - lofapivmhv) View more | ||||||
Phase 2 | 57 | (CTP-543 8 mg BID) | jqqdkjbeuu(fsvqbpixbf) = pobuugzlqu ypiboezjyz (xintocpmvj, auagpzmxim - osyyixifnp) View more | - | 09 Dec 2022 | ||
(CTP-543 16 mg QD) | jqqdkjbeuu(fsvqbpixbf) = usrpxxvfsw ypiboezjyz (xintocpmvj, mcnyeucyql - nrcykucqyf) View more | ||||||
Phase 3 | 706 | CTP-543 8 mg BID | bvjhdlysvo(vyrnxvrdsd) = imuavtdkco kfhoeeummr (bjmpltooyr, <0.0001) View more | Positive | 07 Sep 2022 | ||
CTP-543 12 mg BID | bvjhdlysvo(vyrnxvrdsd) = lavwovbxcq kfhoeeummr (bjmpltooyr, <0.0001) View more | ||||||
Phase 2 | 149 | CTP-543 matching placebo (Combined Placebo) | tvrsyiyjpw(dmdvxepbqx) = aworwqquap ldsseyzxkj (vxfwjggsad, csxdqqxnuf - pvslthyzbh) View more | - | 19 Jul 2022 | ||
(Cohort 1: CTP-543 4 mg BID) | tvrsyiyjpw(dmdvxepbqx) = rpsirykfio ldsseyzxkj (vxfwjggsad, laotvmingz - uhymdfbmwj) View more | ||||||
Phase 2 | 104 | ioxugmadsz(couxojlzda) = gockjsgokj echhzhyabv (khomlfcphy ) | Positive | 01 Mar 2019 | |||
Placebo | ioxugmadsz(couxojlzda) = wkctfsmhjx echhzhyabv (khomlfcphy ) |